Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.
- Filed
- Aug 5, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001367644-26-000082
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Contract liabilities | 6.5 | (0.1) |
| Net cash provided by operating activities | 22.3 | 95.2 |
| Investing Activities | ||
| Purchases of property, plant and equipment | (4.5) | (6.5) |
| Proceeds from sale of property, plant and equipment | 0.2 | 38.2 |
| Milestone payment from prior asset acquisition | (50.4) | — |
| Milestone proceeds from prior asset divestiture | — | 50.0 |
| Purchase of convertible note receivable | — | (5.0) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Emergent Biosolutions's capex?
- Emergent Biosolutions (EBS) reported capex of $2.1M in Q2 2026.
- How has Emergent Biosolutions's capex changed year-over-year?
- Emergent Biosolutions's capex decreased by 27.6% year-over-year, from $2.9M to $2.1M.
- What is the long-term trend for Emergent Biosolutions's capex?
- Over 4 years (2021 to 2025), Emergent Biosolutions's capex has grown at a -50.2% compound annual growth rate (CAGR), from $224.1M to $13.8M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Emergent Biosolutions's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude